


Ophthalmic Images

Symptomatic Netarsudil-Induced Verticillata

Sean S. Rivera, MD; Nicole Radunzel, CRA; Erin A. Boese, MD

A Slitlamp image, right eye



B Slitlamp image, left eye




Figure. Visually significant netarsudil-induced verticillata. Sclerotic scatter slitlamp photographs of the right (A) and left (B) eye demonstrating vortex keratopathy.

An 80-year-old woman presented with new-onset hazy vision and glare for 5 months after starting netarsudil for severe primary open-angle glaucoma. She was noted to have corneal verticillata



CME at jamacmelookup.com

in both eyes (Figure) and conjunctival hyperemia but no corneal edema. Although the visual acuity remained stable at her baseline of 20/25 OD and 20/20 OS, there were no other findings to explain her symptoms, and her symptoms began to

improve just 1 week after discontinuing netarsudil. Netarsudil ophthalmic solution, 0.02%, is a rho-kinase inhibitor used to lower intraocular pressure (IOP) in open-angle glaucoma, and corneal verticillata are a known adverse effect.¹ In the Rho-Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) trials, vortex keratopathy occurred in up to 26% of patients and had no visual relevance.^{2,3} We present our case to make clinicians aware that netarsudil can be associated with corneal changes that may be symptomatic, as in this patient.

ARTICLE INFORMATION

Author Affiliations: Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City.

Corresponding Author: Erin A. Boese, MD, Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, IA 52242 (erin-boese@uiowa.edu).

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

REFERENCES

1. Wu JH, Chang SN, Nishida T, Kuo BI, Lin JW. Intraocular pressure-lowering efficacy and ocular safety of rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials. *Graefes Arch Clin Exp Ophthalmol*. 2022;260(3):937-948. doi:10.1007/s00417-021-05379-7
2. Kahook MY, Serle JB, Mah FS, et al; ROCKET-2 Study Group. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil

ophthalmic solution: rho kinase elevated IOP treatment trial (ROCKET-2). *Am J Ophthalmol*. 2019;200:130-137. doi:10.1016/j.ajo.2019.01.003

3. Serle JB, Katz LJ, McLaurin E, et al; ROCKET-1 and ROCKET-2 Study Groups. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). *Am J Ophthalmol*. 2018;186:116-127. doi:10.1016/j.ajo.2017.11.019